Product Description
a non-dopaminergic treatment for the motor symptoms of Parkinson's disease (Sourced from: https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-2)
Mechanisms of Action: T-Type Calcium Channel Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Praxis
Company Location: Eastern America
Company CEO: Marcio Souza
Additional Commercial Interests: Tenacia Biotechnology
Clinical Description
Countries in Clinic: Australia, Canada, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Praxis presented P3 Essential Tremor|Movement Disorders|Tremor results on 2025-11-05 for Ulixacaltamide
- Clinical Outcomes Reported - Praxis presented P3 Essential Tremor results on 2025-10-16 for Ulixacaltamide
- Clinical Outcomes Reported - Praxis announced they will present P3 Essential Tremor results in 3Q25 for Ulixacaltamide
Highest Development Phases
Phase 3: Essential Tremor|Movement Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06087276 |
PRAX-944-321 | P3 |
Enrolling by invitation |
Essential Tremor|Movement Disorders |
2025-09-01 |
21% |
2025-10-01 |
|
NCT05021991 |
Essential1 | P2 |
Completed |
Essential Tremor |
2023-02-09 |
86% |
2024-03-14 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
ACTRN12619001052123 |
ACTRN12619001052123 | P2 |
Recruiting |
Essential Tremor |
None |
2025-12-29 |
Treatments |
|
ACTRN12622000408785 |
ACTRN12622000408785 | P2 |
Recruiting |
Essential Tremor |
None |
2024-08-29 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/12/2026 |
News Article |
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress |
|
12/29/2025 |
News Article |
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor |
|
12/04/2025 |
News Article |
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor |
|
11/20/2025 |
News Article |
Praxis Precision Medicines to Participate in Upcoming Fireside Chat |
|
05/06/2024 |
PubMed |
Burden and frequency of viral testing of kidney and non-kidney transplant recipients. |
|
04/01/2024 |
PubMed |
Discovery of Ī±-Obscurine Derivatives as Novel Cav3.1 Calcium Channel Blockers. |
|
03/15/2024 |
PubMed |
Effect of ABT-639 on Cav3.2 channel activity and its analgesic actions in mouse models of inflammatory and neuropathic pain. |